遠大醫藥(00512.HK)1,500萬歐元入股XELTIS 引進創新修復產品
遠大醫藥(00512.HK)公布,與XELTIS達成股權投資及產品引進戰略合作協議。集團將以1,500萬歐元取得XELTIS約11%股權,並獲得用於對終末期腎臟病患者建立移植物血管內瘺開展血液透析治療的全球創新內源性組織修復產品aXess以及同技術平台下未來研發的血液透析領域內其他新產品在大中華區(中國、香港、澳門及台灣)的獨家開發、生產及商業化權益。同時,集團還擁有對XELTIS其他適應症領域開發產品在大中華區的優先談判權。
XELTIS位於荷蘭,是一家專注於開發基於超分子聚合物的內源性組織修復設備進行血管相關領域治療的醫療設備公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.